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Abstract: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease 
characterized by progressive muscle wasting and weakness with no effective cure. 
Emerging evidence supports the notion that the abnormal conformations of ALS-linked 
proteins play a central role in triggering the motor neuron degeneration. In particular, 
mutant types of superoxide dismutase 1 (SOD1) and TAR DNA binding protein 43kDa 
(TDP-43) are key molecules involved in the pathogenesis of familial and sporadic ALS, 
respectively. The commonalities of the two proteins include a propensity to aggregate and 
acquire detrimental conformations through oligomerization, fragmentation, or post-translational 
modification that may drive abnormal subcellular localizations. Although SOD1 is a major 
cytosolic protein, mutated SOD1 has been  localized to mitochondria, endoplasmic 
reticulum, and even the extracellular space. The nuclear exclusion of TDP-43 is a pathological 
hallmark for ALS, although the pathogenic priority remains elusive. Nevertheless, these 
abnormal behaviors based on the protein misfolding are believed to induce diverse 
intracellular and extracellular events that may be tightly linked to non-cell-autonomous 
motor neuron death. The generation of mutant- or misfolded protein-specific antibodies 
would help to uncover the distribution and propagation of the ALS-linked proteins, and to 
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design a therapeutic strategy to clear such species. Herein we review the literature 
regarding the mislocalization of ALS-linked proteins, especially mutant SOD1 and TDP-43 
species, and discuss the rationale of molecular targeting strategies including immunotherapy. 
Keywords: seeding; subcellular localization; SOD1; TDP-43; non-cell-autonomous motor 
neuron death; antibody 
 
1. Introduction 
Amyotrophic lateral sclerosis (ALS) is a fatal paralytic disease with no effective cure. Although the 
etiology of ALS remains unclear, the current consensus implicates aberrant conformational changes in 
disease-associated proteins driving the diverse signaling cascades causing ALS [1–3]. The original 
pathological evidence came from case reports describing cellular inclusions either reminiscent of Lewy 
bodies in a familial ALS case [4] or resembling Lafora bodies in a sporadic ALS patient [5]. The Lewy 
body-like hyaline inclusions as well as the skein-like inclusions, are ubiquitinated [6,7], indicating that 
ALS pathogenesis involves protein mishandling.  
Approximately 90–95% of ALS cases are sporadic with unknown etiology. However, intensive 
genetic approaches to familial ALS (FALS) patients have successfully identified diverse ALS-causative 
genes including SOD1, ALS2, SETX, SPG11, FUS, VAPB, ANG, and TDP-43, which are assigned as 
ALS1, 2, 4, 5, 6, 8, 9, and 10, respectively [8]. Moreover, an increasing number of new genes have 
been identified in familial ALS including optineurin [9], ubiquilin2 [10], and an expanded GGGGCC 
hexanucleotide repeat in noncoding region of C9ORF72 [11,12]. Strikingly, the wild type (WT) forms 
of SOD1, TDP-43, and FUS have been detected in pathological inclusions in sporadic ALS, justifying 
the research on familial ALS to understand sporadic cases. Indeed, many signaling mechanisms 
implicated in mutant SOD1-linked ALS may also underlie the pathogenesis of sporadic ALS, 
including mitochondrial damage, glutamate toxicity, proteasome impairment, ER stress, and axonal 
flow strangulation [13,14].  
Physiological functions of the various ALS-associated proteins may vary widely despite the 
characteristic motor symptoms of ALS. This indicates huge diversities in ALS pathogenic mechanisms. 
However, aberrant gene products in ALS, and especially those involved in autosomal dominant 
inheritance such as SOD1, TDP-43, FUS, and, in several cases, optineurin, have been colocalized with 
ubiquitin-positive inclusions [9,15–17], indicating the disturbance of clearance pathways of misfolded 
proteins. Interestingly, the mutant products of these genes show abnormal subcellular distributions in 
cultured cells and affected tissues. For instance, mutant SOD1 protein, a major cytosolic protein, is 
mislocalized to mitochondria, endoplasmic reticulum, and the trans-Golgi network, and each such 
subcellular compartment could be a source of toxic signaling [13]. For example, the redistribution of 
TDP-43 to the cytosol induces aggregate formation and relocates nuclear TDP-43. Therefore, it is 
useful and practical to approach ALS pathogenesis from the standpoint of protein mislocalization 
driven by aberrant conformations.  
Here, we review the roles of two major ALS-linked proteins, SOD1 and TDP-43, with a focus on 
their aberrant subcellular localizations.  Int. J. Mol. Sci. 2011, 12  6982 
 
2. Superoxide Dismutase 1 (SOD1) 
2.1. Molecular Basis 
In 1993, superoxide dismutase 1 (SOD1) was identified as the first genetic mutation in 20% of 
familial ALS patients [18]. SOD1 is an oxidation antagonist found in the cytosol that scavenges the 
superoxide to produce oxygen and hydrogen peroxide (O2
− + H2O → O2 + H2O2). It is one of the most 
abundant cellular proteins comprising about 2% of total cytosolic protein content. To date, more than 
150 SOD1 mutations have been reported, which together cover most of the functional domains [19]. 
Moreover, the enzymatic activity of mutant SOD1 varies from null to “increased” despite similar 
symptoms in overall mutants. Moreover,  SOD1 KO mice show no ALS phenotype  [20]. These 
findings indicated that mutant SOD1-linked ALS is caused not by the loss of anti-oxidant function, but 
by the acquired toxic function resulting from protein conformational change.  
Disulfide formation through this Cys57-Cys146 bond stabilizes the SOD1 structure and maintains 
proper dimerization [21], as shown by the study of Wang et al. [22] in which a substitution mutant of 
cysteine induced the misfolding of SOD1. On the other hand, Cys6 and Cys111 have been implicated 
in oligomer formation under oxidative conditions [22–24]. Considering that the cytosol is a reducing 
environment that would result in cleavage of disulfide bonds, this intramolecular Cys57-Cys146 bridge 
is protected from reduction by the proper dimer conformation. Therefore, it is reasonable to assume 
that a mutation-derived single amino acid replacement might affect the protein dimer structure, leading 
to misfolding, particularly as many mutant SOD1s are readily monomerized under mild reducing 
condition [25]. Rakhit et al. [26] reported that both WT and mutant SOD1 transiently form unnatural 
and partially folded monomers upon oxidation, before oligomerizing or aggregating. Based on these 
findings, the group then generated a rabbit polyclonal antibody against the potential dimer interface 
(SEDI), and demonstrated that this antibody specifically labels misfolded SOD1 [27]. We provided 
further evidence for the significant role of a transient hydrophobic surface by identifying Hsp70-SOD1 
complex, which is present in the detergent-soluble,  but  not in the detergent-insoluble fraction. 
Moreover, demetallating SOD1 augmented the affinity of Hsp/Hsc 70 for SOD1 in both mutant and 
WT protein [28]. Mammalian cells precisely recognize misfolded SOD1 species and direct them for 
degradation through the ubiquitin-proteasome pathway [29]. Therefore, mutant SOD1 has a shorter 
half-life than the WT protein; however, the degradation capability of proteasome is gradually impaired 
under the continued expression of mutant SOD1, leading to the accumulation of ubiquitin-positive 
SOD1 species [29].  
2.2. Toxic Cascades Caused by Mutant SOD1  
SOD1 is a major cytosolic protein. Live-cell imaging of EGFP-fused SOD1 showed a homogenous 
distribution in the cytosol for both WT and mutant SOD1s. However, mild membrane perforation 
using digitonin in the presence of ATP to wash out soluble cytosolic protein unveiled punctate or 
vesicular locations of SOD1 including mitochondria, lysosomes, ER, and trans-Golgi network, and the 
effect was more apparent with the mutant SOD1 than with WT [30].  
Although the molecular basis for these aberrant translocations of mutant SOD1 to various cellular 
organelles remains elusive, the hydrophobic nature of the mutant protein is a possible explanation. Int. J. Mol. Sci. 2011, 12  6983 
 
Okado-Matsumoto and Fridovich [31] documented that the apo state of the SOD1 protein enables it to 
access mitochondria, but the heat shock chaperone prevents entry, indicating that the hydrophobicity 
of SOD1 is a key factor for its translocation to mitochondria [31]. Apo SOD1 can also be directly 
incorporated into microsomes in the presence of ATP in vitro [30]. Although WT SOD1 has also been 
localized at lysosomes, mitochondria, and nucleus as well as in the cytosol [32], it should be noted that 
only the mutant SOD1 causes undesirable detrimental effects on cell survival when redistributed to 
these other locations (Figure 1).  
Figure 1. Aberrant subcellular localization of mutant SOD1 protein and the associated 
effect on ALS pathogenesis. Mutant SOD1 interacts with several “accompanying proteins”, 
resulting in the abnormal subcellular localization. 
 
2.2.1. Mitochondria 
Mitochondria are indispensable suppliers of oxidative energy in addition to their role as calcium 
(Ca
2+) buffers. In neurons, mitochondria are transported to the distal axon, thus mitochondrial damage 
seriously affects the diverse functions of the growth cone and synaptic terminals. Indeed, blocking 
Ca
2+ entry into mitochondria rescues cultured motor neurons from glutamate-induced cell death [33]. 
The role of mitochondria in mutant SOD1-linked ALS was first studied using a transgenic approach by 
Wong et al. [34], who demonstrated a prominent vacuolar change to mitochondria in G37R SOD1 Tg 
mice. Later work revealed mutant SOD1 inside mitochondria in mutant SOD1 Tg mice by 
immunofluorescence and immunoelectron microscopy [35]. Distinct from WT SOD1, mutant SOD1 
induces morphological change and cytochrome c release in cultured neurons that resulted in   
apoptosis [36]. Two transgenic studies further indicated the involvement of mitochondria-mediated 
apoptosis in mutant SOD1-linked ALS. Inoue et al. [37] demonstrated that suppressing caspase-9 by 
overexpressing XIAP in motor neurons effectively slowed the progression of ALS in G93A SOD1 Tg 
mice, while Reyes et al. documented that neuron-specific deletion of BCL-associated X protein (BAX) 
or BCL2-homologous antagonist/killer (BAK), which are both proapoptotic BCL-2 family   Int. J. Mol. Sci. 2011, 12  6984 
 
proteins, delayed the onset and extended the longevity of disease in the same mice [38]. In addition,  
Vande Velde et al. [39] used sophisticated double transgenic mice co-expressing mutant SOD1 and a 
mitochondria-targeted fluorescent indicator to demonstrate aberrant morphology and distribution of 
mitochondria. Interestingly, these altered properties were influenced by the dismutase activity of 
SOD1, whereby dismutase-active G37R SOD1 induces mitochondrial clustering in the proximal site, 
whereas dismutase-inactive G85R SOD1 produces aberrantly elongated mitochondria in the axon, 
indicating that oxidative stress modifies the detrimental effect of mutant SOD1  [39]. One of the 
proposed molecules responsible for the entry of mutant SOD1 into mitochondria is a voltage-dependent 
anion channel (VDAC1), which resides in the mitochondrial outer membrane [40]. Mutant, but not 
WT SOD1, interacts with VDAC1, and the ablation of VDAC1 in G37R SOD1 Tg mice slowed the 
onset of paralysis. Mitochondria are the major source of reactive oxygen species (ROS) in cells, and 
these could contribute to the observed motor neuron death. However, conditional knockout of SOD2, a 
mitochondrial SOD, in the motor neurons produced no ALS phenotype  [41], arguing against the 
hypothesis that mitochondrial ROS are a trigger for ALS. Surprisingly, a recent study by Zhu and 
Sheng [42] revealed that mutant SOD1 Tg mice with increased mitochondrial mobility in the motor 
neuron axons displayed a similar phenotype to those with impaired mobility. This result suggested that 
mislocalization of mitochondria alone is not enough to explain the detrimental events caused by the 
axonal transport impairment, and the malfunction of mitochondria themselves may be directly 
responsible for the ALS pathogenesis.  
2.2.2. Endoplasmic Reticulum (ER) 
Previously, the only luminal structures to which the SOD1 redistributed were regarded to be 
lysosomes and mitochondria [43]. Only one paper using hepatocytes had shown SOD1 in the ER [44]. 
However, Tobisawa et al. [45] showed that mutant SOD1, but not WT protein, colocalized with ER 
chaperone protein, GRP78/Bip, and induced ER stress in the transfected cells. Studies by our group [46] 
and by Kikuchi et al. [47] used immunoelectron microscopy to more precisely localize the mutant 
SOD1 in ER. Kikuchi et al. also demonstrated that mutant SOD1 interacts with GRP78/Bip, which 
mediates its entry into ER. We further confirmed the ER localization of SOD1 by sucrose density-gradient 
ultracentrifugation and floating ultracentrifugation using an iodixanol cushion and high-salt wash [30], 
while a recent paper demonstrated both WT and mutant SOD1 in microsome fractions and partial 
colocalization of these proteins with Derlin-1 in ER by immunocytochemistry [48].  
ER stress is triggered by the accumulation of unfolded protein in the ER through the activation of 
three sensor proteins, IRE1, ATF6, and PERK, which downregulate protein synthesis and up-regulate 
BiP/GRP78  [49]. ER stress is thought to play a crucial role in both sporadic and familial ALS 
pathogenesis [50–54]. The ablation of BH3-only protein puma, which is necessary to induce ER stress, 
significantly delayed the disease onset and protected motor neurons [55]. However, the molecular 
mechanisms  by which mutant SOD1 induces ER stress remains unclear. Notably, ER-targeted 
overexpression of mutant SOD1 did not injure Neuro2a cells [36], suggesting the existence of partner 
molecules inside or adjacent to ER that are involved in mutant SOD1-induced ER stress. To this end, 
Nishitoh et al. [56] reported that cytosolic mutant SOD1 induced ER stress through an interaction with 
Derlin-1, leading to an impaired unfolded stress response and the activation of apoptosis signal-regulating Int. J. Mol. Sci. 2011, 12  6985 
 
kinase 1 (ASK1). In addition, protein disulfide isomerase, which is upregulated under ER stress, shows 
therapeutic potential based on its amelioration of cell toxicity induced by the unfolded stress response [57]. 
2.2.3. Golgi Apparatus, Secretory Pathway 
Another noxious effect of ER stress caused by mutant SOD1 is fragmentation of the Golgi 
apparatus, which affects protein maturation and intracellular trafficking of membrane and secretory 
proteins [58]. Indeed, Gonatas and coworkers [59] clearly showed a fragmented Golgi apparatus in the 
motor neurons of ALS patients. This does not necessarily mean that mutant SOD1 is present in the 
Golgi apparatus, since Golgi morphology is affected by the structural dynamism of microtubules for 
axoplasmic transport. Indeed, SOD1 is synthesized in free ribosomes, and has no signal peptide that 
drives the entry of proteins into the ER-Golgi secretory pathway. Therefore, despite early findings of 
WT SOD1 secreted from cultured astrocytes and thymus-derived epithelial and fibroblast cells, 
secretion  of SOD1 is thought to follow a non-classical pathway since brefeldin A, an ER-Golgi 
transport blocker, did not inhibit the secretion [60].  
More recently, Turner et al. [61] presented compelling evidence that both WT and mutant SOD1  
are trafficked via the classical secretory pathway. In addition to morphological evidence using 
immunoelectron microscopy, we confirmed the presence of mutant SOD1 in trans-Golgi network of 
mutant SOD1 Tg mice by immunoisolating the organelle using a Golgi-resident protein, TGN38 [46]. 
The molecular mechanism used by mutant SOD1 to enter the secretory pathway remains elusive. We 
identified chromogranin A (ChgA) and B (ChgB), which are neurosecretory proteins, as interacting 
partners with mutant SOD1, but not WT. Mutant SOD1 and chromogranins interact and colocalize in 
the G37R and G93A SOD1 transgenic mice, as verified by double immunoelectron microscopy and 
immunoprecipitation [46]. In addition, both ChgA and ChgB promote the secretion of mutant SOD1, 
but not WT protein, in cell culture experiments. The potential effects of this secreted and extracellular 
SOD1 on ALS pathogenesis are discussed below.  
2.3. Cell-Autonomous and Non-Cell-Autonomous Motor Neuron Degeneration  
The overexpression of mutant SOD1, but not WT, induces apoptotic cell death [36,62,63], with 
mutant SOD1 inducing diverse toxic signaling pathways inside cells, including those driving 
mitochondrial impairment, ER stress, oxidative stress, and proteasome suppression. However, an 
earlier study showed that transgenic mice expressing mutant SOD1 predominantly in the motor neuron 
do not develop ALS [64], while Lino and coworkers [65] showed that mutant SOD1 expression driven 
by the Thy-1 promoter neither produced an ALS phenotype nor affected the progression of mutant 
SOD1 Tg mice. On the other hand, transgenic mice harboring GFAP promoter-driven mutant SOD1 
showed no palsy, but did show massive astrogliosis [66]. The interplay between motor neurons and 
glial cells has been intensively investigated by Cleveland’s laboratory. First, Clement et al. [67] 
generated chimeric transgenic mice by randomly mixing morula from mutant SOD1 Tg and control 
mice (NF-L Tg mice or YFP mice). Their analysis revealed that the number of surrounding cells 
expressing mutant SOD1 regulates the survival of motor neurons. Specifically, mutant SOD1-expressing 
motor neurons were not injured if the surrounding cells were non-transgenic. Further studies on the 
role of motor neurons and glial cells in disease onset and progression, using Cre-loxP system showed Int. J. Mol. Sci. 2011, 12  6986 
 
that cell-specific downregulation of G37R mutant SOD1 in motor neurons or microglia delays the 
development or progression, respectively [67]. Yamanaka et al. [68] further showed mutant SOD1 in 
astrocytes plays a crucial role in slowing the progression. This series of studies established the notion 
that mutant SOD1-induced ALS is mediated by non-cell-autonomous machinery. It should be noted 
that the type of mutation and promoter used in the experiments would influence these phenomena. 
Wang et al. then showed that depleting the G85R SOD1 mutant in astrocytes delayed the onset and 
slowed progression of the early symptomatic phase of ALS [69]. This group also documented that 
restricted expression of the G93A mutant in motor neurons and inter-neurons caused a mild clinical 
and pathological phenotype [70].  
Two independent laboratories recently reported that mutant SOD1-expressing astrocytes secrete 
molecules that are toxic only to motor neurons [71,72]. One group identified several candidates for 
these molecules including prostaglandin D2 (PGD2) receptor, Mcp2, Cxcl7, and Rantes [73]. However, 
a PGD2 inhibitor only partial rescued the function of motor neurons cultured on monolayers of the 
mutant SOD1-expressing astrocytes; these cells also activate NOX2 to produce superoxide, which may 
be involved in motor neuron death [73]. Finally, mutant SOD1-expressing microglia were found to 
produce higher superoxide and nitrite, but lower IGF-1, than WT microglia, and these effects were 
augmented by LPS stimulation [74].  
2.4. The Role of Extracellular SOD1 Mutants in the Non-Cell-Autonomous Pathology of ALS  
The findings on this topic can be summarized as follows: 
(1)  The density of mutant SOD1-expressing cells in the anterior horns governs motor neuron 
survival; 
(2)  Mutant SOD1 in motor neurons or glial cells does indeed induce intracellular damage, and 
the motor neuron degeneration is accomplished by summation of these phenomena; 
(3)  Most of the chemical mediators identified so far are reactive oxygen species or 
proinflammatory molecules. 
Based on our discovery of neurosecretory protein chromogranins as binding partners for   
mutant SOD1, we hypothesized that mutant SOD1 itself is a mediator of intercellular crosstalk in  
non-cell-autonomous motor neuron death. Indeed, mutant SOD1 secreted into the culture media, or 
externally applied recombinant mutant SOD1 protein, activates microglial cell lines and induces motor 
neuron death in culture [46]. We also documented that the toxicity of extracellular SOD1 mutant is 
mediated by CD14 on the microglia  [75]. Moreover, overexpression of ChgA in G37R SOD1 Tg   
mice accelerated the disease onset and gliosis  [76], while misfolded SOD1 was detected in the 
cerebrospinal fluid of patients with familial ALS using antibodies specifically recognizing misfolded 
SOD1 species [77,78].  
2.5. WT SOD1 
Interestingly, even WT SOD1 is misfolded by un- or de-metallation, and is recognized by Hsc70  
in vitro  [28]. Moreover, oxidation of WT SOD1 by H2O2  both  in vitro  and  in vivo  induces its 
misfolding and confers toxic effects on cultured motor neurons as well [79]. The role of WT SOD1 in Int. J. Mol. Sci. 2011, 12  6987 
 
sporadic ALS is a matter of debate. Liu et al. [77] failed to detect misfolded SOD1 species in the 
lumbar spinal cord tissues of sporadic ALS patients using the SEDI antibody, while mutant SOD1 was 
immunoprecipitated by the same antibody from SOD1-linked familial ALS patients [77]. On the other 
hand, some work has suggested the involvement of SOD1 in the pathogenesis of sporadic cases as well. 
Gruzman et al. [80] showed that aberrantly dimerized SOD1 is a common finding in spinal cord 
lysates from sporadic and mutant SOD1-linked familial ALS patients, and recently, motor neurons of 
sporadic ALS patients were labeled by the monoclonal antibody (C4F6), which recognizes misfolded 
SOD1 protein, but not natively folded WT SOD1  [81]. Strikingly, Haidet-Phillips  et al. [82] 
documented using iPS cells-derived astrocytes from ALS patients, that SOD1 is a target in the toxic 
machinery in astrocytes in familial and sporadic ALS. The misfolded SOD1 is indeed detected in the 
CSF of sporadic ALS patients using the antibody against misfolded SOD1, although its concentration 
is not high enough to induce motor neuron death  [78]. However, posttranslational modifications, 
including oligomerization of a small fraction of SOD1 protein, would enhance the pathogenicity.  
3. TAR DNA Binding Protein-43kDa (TDP-43)  
In 2006, a groundbreaking discovery came from two independent research groups. A nuclear 
protein, TDP-43, was identified as a core protein of ubiquitinated inclusions of frontotemporal lobar 
degeneration with ubiquitinated inclusions (FTLD-U) and ALS [83,84]. Genetic mutations in TDP-43 
have been detected in a fraction of familial ALS patients with or without FTLD, with several 
exceptions including pure FTLD [85], FTLD with progressive supranuclear palsy and chorea [86], and 
FTLD with Parkinsonism [87]. These lines of evidence indicate a primary role for TDP-43 in the 
development of ALS.  
TDP-43 is a DNA/RNA binding protein, the physiological functions of which have been 
increasingly uncovered, including splicing or stabilization of RNA. The exon 9 skipping of the cystic 
fibrosis transmembrane receptor (CFTR) is a splicing example of TDP-43 [88]. In relevance to ALS, 
neurofilament light chain (NFL) mRNA was the first candidate target RNA to be recognized as 
stabilized by TDP-43  [89]. Recent attempts to grossly screen TDP-43-associated mRNAs using   
cross-linking and immunoprecipitation (CLIP) from brains of FTLD patients [90], mice brain with or 
without ablation of TDP-43 by siRNA  [91], and human neuroblastoma cell line SHSY-5Y  [92] 
revealed that huge amounts of RNA that bind TDP-43, which interacts with introns at UG/TG-rich 
repeat motifs of various mRNAs associated with neuronal development and neurological diseases, 
including TDP-43 itself and progranulin [90–92]. Knocking down TDP-43 in HeLa cells induced 
apoptosis via the upregulation of cyclin-dependent kinase 6 (cdk6) [93], while TDP-43 deletion in 
Caenorhabditis elegans downregulates histone deacetylase 6 (HDAC6), causing aggregate formation 
and promotion of the cytotoxicity caused by polyglutamine-expanded ataxin-3  [94]. TDP-43 
knockdown in neuronal cultures also inactivated Rho family GTPases, including RhoA, Rac1, and 
Cdc42, leading to the inhibition of neurite outgrowth and cell death [95]. Based on these data, the 
current consensus on TDP-43-linked ALS pathogenesis argues for protein misfolding and defective 
RNA processing [96]. Int. J. Mol. Sci. 2011, 12  6988 
 
3.1. Cytosolic Redistribution of TDP-43 in ALS Pathogenesis  
The original and consensus findings for TDP-43 pathologies include the aberrant cytosolic 
redistribution and the ubiquitinated and phosphorylated inclusions [83,84]. We have shown that both 
WT and mutant TDP-43 are constitutively polyubiquitinated, and are degraded in proteasomes and 
autophagosomes [97]. TDP-43 pathology is rarely detected in mutant SOD1-linked ALS, raising the 
question as to whether these two diseases are essentially different  [98]. However, accumulating 
evidence indicates that long-lived mutant SOD1 Tg mice and a fraction of familial ALS patients with 
mutant SOD1 show TDP-43 pathology [99]. We also reported a familial ALS patient, with an I112T 
mutation  in SOD1, presenting with massive expression of phosphorylated TDP-43 in the motor 
neurons of the brainstem and cervical cord  [100]. Notably, TDP-43 redistribution has also been 
reported observed in several conditions not related to ALS or FTLD, including Perry syndrome [101],  
Lewy-body disease [102], Huntington disease [103], and inclusion body myositis [104]. Axonal injury 
also induces a transient redistribution of TDP-43 in rodent motor neurons [105,106]. 
3.2. Nuclear Localizing Signal (NLS) and the Responsible Domains for Cytosolic Redistribution  
TDP-43 contains a bipartite lysine-  or arginine-rich nuclear translocation signal (NLS) and   
leucine-rich nuclear export signal (NES),  with nuclear-cytosol shuttling regulated by the importin 
system [105,107]. Substituting the NLS amino acids effectively altered the nuclear localization of 
TDP-43  [97,108]. In particular, modifying  both NLS residues more efficiently induced cytosolic 
aggregates to be formed than a single amino acid alteration [108]. Studies by Arai et al. [83] and 
Neumann et al. [84] identified 35-kDa or 25-kDa fragments in the affected lesions of ALS or FTLD 
patients. TDP-43 possesses amino acid sequences that mimic caspase recognition sites just carboxyl to 
the NLS, and the cleavage of these also generated 25-kDa and 35-kDa fragments in the cytosol [109]. 
Importantly, Nishimoto et al. showed TDP-43 fragments of the same molecular sizes produced in the 
absence of caspase, and that these fragments are also generated as alternate isoforms [110]. This 
finding suggested that the fragmentation of TDP-43 could be a primary event in triggering ALS, 
although it remains unclear whether the generation of such aberrant isoforms is a regulated or random 
event. The cytosolic aggregates were predominantly carboxyl fragments, since they were labeled mostly 
by anti-C-terminal TDP-43, but much less frequently by the antibody recognizing N-terminus [111]. 
Accumulating evidence shows that the C-terminus of TDP-43 has a higher propensity for aggregate 
formation than other domains [112–114]. However, it should be noted that carboxyl fragments without 
the 2
nd RNA binding domain, RRM2 do not form cytosolic aggregates [115]. In agreement with this, 
recent studies highlighted the importance of RRM2 domains in the cytosolic redistribution or 
aggregate formation of TDP-43 [114–116], although the molecular basis by which RRM2 would be 
involved in the TDP-43 misfolding remains unclear. In addition, RRM1, the 1
st RNA binding domain, 
together with the amino terminal fragment of TDP-43 reportedly mediates dimer formation in 
transfected cells in culture [117]. The possible roles for the various TDP-43 fragments in cytosolic 
aggregate formation are summarized in Figure 2.  Int. J. Mol. Sci. 2011, 12  6989 
 
Figure 2. Fragments of TDP-43 and their effects on aggregate propensity or cytotoxicity. 
Black bars are reported to generate cytosolic aggregates or to induce cell death in vitro and 
in vivo. Grey bars were shown not to provide detrimental effects. Amino acid sequence and 
its source reference are indicated under each bar. References in square brackets are shown 
in the Reference section. 
 
3.3. Pathogenic Role of Mislocalized TDP-43 in the Cytosol  
The possible role of cytosolic TDP-43 as a trigger for ALS pathology remains unclear. In yeast, 
TDP-43 fragments without a functional NLS domain redistributed into the cytosol, although only those 
fragments containing the entire RRM2 and the carboxyl terminus induced toxicity [118]. Moreover, Tg 
mice expressing TDP-43 with an NLS substitution to alanine showed massive cytosolic aggregates and 
neuronal death [119]. On the other hand, a study in C. elegans revealed the motor phenotype only in 
the presence of both RRM1 and RRM2 together with the carboxyl terminal, while NLS-defective 
TDP-43 showed no motor impairment [120]. Aggregate formation of TDP-43 does not immediately 
follow its cytosolic redistribution, and using the elegant in vivo cleavage system with TEV protease, 
Pesiridis et al. [116] found that aggregates containing carboxyl fragments of TDP-43 were actually 
prompted by the disruption of dynein-mediated transport and RNA interaction. It should also be noted 
that the cytosolic redistribution of TDP-43 induces nuclear exclusion of the endogenous TDP-43 [108], 
which may  link  to the loss of function of nuclear TDP-43.  On the other hand, the  cytosolic 
redistribution of TDP-43  does not lead to neurodegeneration in either WT or mutant TDP-43 Tg   
mice [121,122]. Finally, we found that polyubiquitinated TDP-43 is present to a similar extent between Int. J. Mol. Sci. 2011, 12  6990 
 
WT and NLS-defective TDP-43, arguing against the early notion that nuclear exclusion triggers the 
polyubiquitination of TDP-43 [97]. 
3.4. WT and Mutant TDP-43 in Motor Neuron Degeneration  
Over 40 mutations involving amino acid replacement have been reported in TDP-43 [123], with 
most located in the carboxyl terminus (267-414), one mutation (D169G) in RRM1 (103-183), and two 
(Y214Y, P225P) in RRM2 (190-26) (Table 1). Biochemical studies suggested that mutant TDP-43 has 
a higher propensity for aggregate formation and carboxyl termini fragmentation of 25- or 35-kDa 
fragments [124–127]. Moreover, the overexpression of mutant TDP-43 induces cell death in chick 
embryonic spinal motor neurons [126], primary motor neuron cultures [124], C. elegans [128], and 
transgenic rodents [121,129,130]. Swarup et al. [131] found a moderate phenotype expressed by Tg 
mice driven by the native promoter of human TDP-43, including cognitive impairment and motor 
coordination with massive cytosolic redistribution of TDP-43, while  ALS-linked mutant TDP-43 
proteins more readily aggregate in stress granules (SG) than the WT protein [132].  
Table 1. Previously identified genetic mutations in TDP-43. Mutations in the exon in 
regard with the cell toxicity are shown.  
Domain  Mutation  Cell death  Reference 
N-terminus 
D65E    [133] 
A66A    [133] 
A90V    [126] 
RRM1  D169G    [124] 
RRM2 
Y214Y    [134] 
P225P    [133] 
N267S    [135] 
Glycine-rich 
G287S    [136] 
G290A    [137] 
G290S    [136] 
G294A    [126] 
G294V    [136] 
G295R    [135] 
G295S    [135] 
G298S    [137] 
M311V    [136] 
C-terminus 
A315A    [133] 
A315T  Tg mice, Cultured cells, Zebrafish  [124,131] 
Q331K  Cultured cells  [126] 
S332N    [135] 
G335D    [136] 
M337V  Tg rat, Cultured cells, Zebrafish, chick embryo  [125,126,129] 
Q343R    [136] 
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Table 1. Cont. 
Domain  Mutation  Cell death  Reference 
C-terminus 
N345K    [136] 
G348C  Tg mice, Cultured cells, Zebrafish  [124,131] 
N352N    [133] 
N352S    [136] 
[144] 61S    [124] 
P363A    [136] 
Y374X    [136] 
S379C    [136] 
S379P    [135] 
A382P    [136] 
A382T    [124] 
I383V    [136] 
N390D    [124] 
N390S    [136] 
S393L    [135] 
Our review of the literature found limited types of mutations that induce cell death in cultured cells 
or Tg mice and all of these are located between the carboxyl terminus and the glycine-rich domain 
(Table 1). Further studies are needed to investigate the effect of mutations in other parts of the TDP-43 
protein such as RRM1, RRM2, or the glycine-rich domains. WT TDP-43 transgenic mice have also 
showed motor neuron degeneration with paralysis [123,131], although several other studies observed 
no overt phenotype [129,130].  
It remains a matter of debate whether TDP-43-induced ALS is caused by a loss or gain of protein 
function. A sciatic axotomy upregulates TDP-43 in rodents [106], and the expression level of TDP-43 
in ALS patients was up to twice that in non-ALS control [131]. It should also be noted that the aberrant 
cytosolic TDP-43 brings endogenous TDP-43 to the cytosol, inducing loss of TDP-43 function in the 
nucleus. Further investigation comparing the temporal profiles of TDP-43 expression levels and the 
mislocalization of TDP-43, at least in vivo, would further our understanding of the TDP-43 proteinopathy.  
4. Aberrant Localization and Therapeutic Hints 
Non-cell autonomous neuronal cell death has been implicated in various neurodegenerative   
diseases [13]. The recent notion that disease-causative proteins can also affect neighboring cells via 
secretion is attracting significant attention as a possible mechanism underlying the temporal and spatial 
progression of disease [138,139]. Studies have shown that phosphorylated tau [140], α-synuclein [141], 
and Huntingtin [142] proteins can spread out and behave like a prion protein in cell culture models of 
Alzheimer’s, Parkinson’s, and Huntington’s disease, respectively. Moreover, SOD1 aggregates in the 
culture media were recently detected inside cells, supporting a prion-like behavior of the misfolded 
SOD1 [143]. Aggregated SOD1 also acquires a seeding effect in which recombinant mutant SOD1 
accelerates fibril formation of previously folded SOD1 species [144]. Furthermore, a recent paper has 
provided evidence that mutant or misfolded human SOD1 induces a species-specific conformational 
conversion of native WT SOD1 to misfolded species, which is surprisingly mediated by the tryptophan Int. J. Mol. Sci. 2011, 12  6992 
 
at 32 amino acid residue  [145].  We and others proved that extracellular SOD1 mutant can be a 
therapeutic target for vaccination or antibody therapy against misfolded SOD1 [146–148]. In the case 
of TDP-43, mounting data supports that TDP-43 aggregates have a seeding effect in vitro [114,149], 
although the possible spreading of TDP-43 is not proven. However, considering the clinical evidence 
that cerebrospinal fluid TDP-43 [150–152], it is possible that TDP-43 also behaves like a prion. In this 
sense, if mislocalized TDP-43 triggers loss of function of nuclear TDP-43, elimination of cytosolic 
TDP-43 is a challenging but attractive therapeutic strategy. For instance, the monoclonal antibody 
strategy could have extensive applications clinically including using intrabody or Fab molecules for 
molecular targeting of such species.  
5. Conclusions  
We present evidence in this review that the misdirection of the ALS-linked proteins can ultimately 
account for various pathological signaling. The efficacy of any molecular targeting strategy depends 
on our understanding of the aberrant subcellular localization of these proteins. Further investigation is 
required to uncover the molecular basis and the downstream cascades of the mislocalized, ALS-linked 
proteins to develop more innovative therapy.  
Acknowledgment 
This work is supported by KEKENHI  23300131  for  Scientific Research (B),  22659171  for 
Challenging Exploratory Research, and Grant-in Aid 23111002 for Scientific Research on Innovative 
Areas from Ministry of Education, Culture, Sports, Science & Technology (MEXT), and a Grant for 
Research on Neurodegenerative Diseases from Japan Health and Labour Science (M.U.).  
References 
1.  Kabashi, E.; Durham, H.D. Failure of protein quality control in amyotrophic lateral sclerosis. 
Biochim. Biophys. Acta 2006, 1762, 1038–1050. 
2.  Hart, P.J. Pathogenic superoxide dismutase structure, folding, aggregation and turnover. Curr. 
Opin. Chem. Biol. 2006, 10, 131–138. 
3.  Ticozzi, N.; Ratti, A.; Silani, V. Protein aggregation and defective RNA metabolism as 
mechanisms for motor neuron damage. CNS Neurol. Disord. Drug Targets 2010, 9, 285–296. 
4.  Takahashi, K.; Nakamura, H.; Okada, E. Hereditary amyotrophic lateral sclerosis. Histochemical 
and electron microscopic study of hyaline inclusions in motor neurons. Arch. Neurol. 1972,  
27, 292–299. 
5.  Sun,  C.N.; Araoz, C.; Lucas, G.; Morgan, P.N.;  White, H.J. Amyotrophic lateral sclerosis. 
Inclusion bodies in a case of the classic sporadic form. Ann. Clin. Lab. Sci. 1975, 5, 38–44. 
6.  Murayama, S.; Ookawa, Y.; Mori, H.; Nakano, I.; Ihara, Y.; Kuzuhara, S.;  Tomonaga, M. 
Immunocytochemical and ultrastructural study of Lewy body-like hyaline inclusions in familial 
amyotrophic lateral sclerosis. Acta Neuropathol. (Berl.) 1989, 78, 143–152. 
7.  Mizusawa, H.; Nakamura, H.; Wakayama, I.; Yen, S.H.; Hirano, A. Skein-like inclusions in the 
anterior horn cells in motor neuron disease. J. Neurol. Sci. 1991, 105, 14–21. Int. J. Mol. Sci. 2011, 12  6993 
 
8.  Traub, R.; Mitsumoto, H.; Rowland, L.P. Research advances in amyotrophic lateral sclerosis, 
2009 to 2010. Curr. Neurol. Neurosci. Rep. 2011, 11, 67–77. 
9.  Maruyama, H.; Morino, H.; Ito, H.; Izumi, Y.; Kato, H.; Watanabe, Y.; Kinoshita, Y.; Kamada, M.; 
Nodera, H.; Suzuki, H.; et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 
2010, 465, 223–226. 
10.  Deng, H.X.; Chen, W.; Hong, S.T.; Boycott, K.M.; Gorrie, G.H.; Siddique, N.; Yang, Y.;   
Fecto, F.; Shi, Y.; Zhai, H.; et al. Mutations in UBQLN2 cause dominant X-linked juvenile and 
adult-onset ALS and ALS/dementia. Nature 2011, 477, 211–215. 
11.  Renton, A.E.; Majounie, E.; Waite, A.; Simón-Sánchez, J.; Rollinson, S.; Gibbs, J.R.;   
Schymick, J.C.; Laaksovirta, H.; van Swieten, J.C.; Myllykangas, L.; et al. A Hexanucleotide 
repeat expansion in C9ORF72 is the cause of chromosome 9p21-Linked ALS-FTD. Neuron 2011, 
in press. 
12.  Dejesus-Hernandez, M.; Mackenzie, I.R.; Boeve, B.F.; Boxer, A.L.; Baker, M.; Rutherford, N.J.; 
Nicholson, A.M.; Finch, N.A.; Flynn, H.; Adamson, J.; et al. Expanded GGGGCC hexanucleotide 
repeat in noncoding region of C9ORF72 causes chromosome 9p-Linked FTD and ALS. Neuron 
2011, in press. 
13.  Ilieva, H.; Polymenidou, M.; Cleveland, D.W. Non-cell autonomous toxicity in neurodegenerative 
disorders: ALS and beyond. J. Cell Biol. 2009, 187, 761–772. 
14.  Bento-Abreu, A.; Van Damme, P.; Van Den Bosch, L.; Robberecht, W. The neurobiology of 
amyotrophic lateral sclerosis. Eur. J. Neurosci. 2010, 31, 2247–2265. 
15.  Kato, S.; Takikawa, M.; Nakashima, K.; Hirano, A.; Cleveland, D.W.; Kusaka, H.; Shibata, N.; 
Kato, M.; Nakano, I.;  Ohama, E. New consensus research on neuropathological aspects of 
familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: 
Inclusions containing SOD1 in neurons and astrocytes. Amyotroph. Lateral Scler. 2000, 1, 163–184. 
16.  Yokoseki, A.; Shiga, A.; Tan, C.F.; Tagawa, A.; Kaneko, H.; Koyama, A.; Eguchi, H.; Tsujino, A.; 
Ikeuchi, T.; Kakita, A.; et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann. 
Neurol. 2008, 63, 538–542. 
17.  Tateishi, T.; Hokonohara, T.; Yamasaki, R.; Miura, S.; Kikuchi, H.; Iwaki, A.; Tashiro, H.; 
Furuya, H.; Nagara, Y.; Ohyagi, Y.;  et al. Multiple system degeneration with basophilic 
inclusions in Japanese ALS patients with FUS mutation. Acta Neuropathol. (Berl.)  2010,  
119, 355–364. 
18.  Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; 
Goto, J.; O’Regan, J.P.; Deng, H.X.; et al. Mutations in Cu/Zn superoxide dismutase gene are 
associated with familial amyotrophic lateral sclerosis. Nature 1993, 362, 59–62. 
19.  University of Tokyo. ALS Mutation Database, 2011. Available online: https://reseq.lifesciencedb. 
jp/resequence/GeneDetail.do?targetId=1&geneId=EG6647 (accessed on 12 October 2011). 
20.  Reaume, A.G.; Elliott, J.L.; Hoffman, E.K.; Kowall, N.W.; Ferrante, R.J.; Siwek, D.F.;   
Wilcox, H.M.; Flood, D.G.; Beal, M.F.; Brown,  R.H., Jr.;  et al. Motor neurons in Cu/Zn 
superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after 
axonal injury. Nat. Genet. 1996, 13, 43–47. Int. J. Mol. Sci. 2011, 12  6994 
 
21.  Furukawa, Y.; Fu, R.; Deng, H.X.; Siddique, T.; O’halloran, T.V. From the Cover: Disulfide 
cross-linked protein represents a significant fraction of ALS-associated Cu, Zn-superoxide 
dismutase aggregates in spinal cords of model mice. Proc. Natl. Acad. Sci. USA  2005,  
280, 7148–7153. 
22.  Wang, J.; Xu, G.;  Borchelt, D.R. Mapping superoxide dismutase 1 domains of non-native 
interaction: roles of intra- and intermolecular disulfide bonding in aggregation. J. Neurochem. 
2006, 96, 1277–1288. 
23.  Watanabe, S.; Nagano, S.; Duce, J.; Kiaei, M.; Li, Q.X.; Tucker, S.M.; Tiwari, A.; Brown, R.H., Jr.; 
Beal, M.F.; Hayward, L.J.; et al. Increased affinity for copper mediated by cysteine 111 in forms 
of mutant superoxide dismutase 1 linked to amyotrophic lateral sclerosis. Free Radic. Biol. Med. 
2007, 42, 1534–1542. 
24.  Fujiwara, N.; Nakano, M.; Kato, S.; Yoshihara, D.; Ookawara, T.; Eguchi, H.; Taniguchi, N.; 
Suzuki, K. Oxidative modification to cysteine sulfonic Acid of cys111 in human copper-zinc 
superoxide dismutase. J. Biol. Chem. 2007, 282, 35933–35944. 
25.  Tiwari, A.;  Hayward, L.J. Familial amyotrophic lateral sclerosis mutants of copper/zinc 
superoxide dismutase are susceptible to disulfide reduction. J. Biol. Chem. 2003, 278, 5984–5992. 
26.  Rakhit, R.; Crow, J.P.; Lepock, J.R.; Kondejewski, L.H.; Cashman, N.R.;  Chakrabartty, A. 
Monomeric Cu,  Zn-superoxide dismutase is a common misfolding intermediate in the   
oxidation models of sporadic and familial amyotrophic lateral sclerosis. J. Biol. Chem. 2002,  
277, 15499–15504. 
27.  Rakhit, R.; Robertson, J.; Vande Velde, C.; Horne, P.; Ruth, D.M.; Griffin, J.; Cleveland, D.W.; 
Cashman, N.R.;  Chakrabartty, A. An immunological epitope selective for pathological 
monomer-misfolded SOD1 in ALS. Nat. Med. 2007, 13, 754–759. 
28.  Urushitani, M.; Kurisu, J.; Tateno, M.; Hatakeyama, S.; Nakayama, K.; Kato, S.; Takahashi, R. 
CHIP promotes proteasomal degradation of familial ALS-linked mutant SOD1 by ubiquitinating 
Hsp/Hsc70. J. Neurochem. 2004, 90, 231–244. 
29.  Urushitani, M.; Kurisu, J.; Tsukita, K.;  Takahashi, R. Proteasomal inhibition by misfolded 
mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic 
lateral sclerosis. J. Neurochem. 2002, 83, 1030–1042. 
30.  Urushitani, M.; Ezzi, S.A.; Matsuo, A.; Tooyama, I.; Julien, J.P. The endoplasmic reticulum-
Golgi pathway is a target for translocation and aggregation of mutant superoxide dismutase 
linked to ALS. FASEB J. 2008, 22, 2476–2487. 
31.  Okado-Matsumoto, A.; Fridovich, I. Amyotrophic lateral sclerosis: a proposed mechanism. Proc. 
Natl. Acad. Sci. USA 2002, 99, 9010–9014. 
32.  Shaw, B.F.; Valentine, J.S. How do ALS-associated mutations in superoxide dismutase 1 
promote aggregation of the protein? Trends Biochem. Sci. 2007, 32, 78–85. 
33.  Urushitani, M.; Nakamizo, T.; Inoue, R.; Sawada, H.; Kihara, T.; Honda,  K.; Akaike, A.; 
Shimohama, S. N-methyl-D-aspartate receptor-mediated mitochondrial Ca(2+) overload in acute 
excitotoxic motor neuron death: A mechanism distinct from chronic neurotoxicity after Ca(2+) 
influx. J. Neurosci. Res. 2001, 63, 377–387. Int. J. Mol. Sci. 2011, 12  6995 
 
34.  Wong, P.C.; Pardo, C.A.; Borchelt, D.R.; Lee, M.K.; Copeland, N.G.; Jenkins, N.A.;   
Sisodia, S.S.; Cleveland, D.W.; Price, D.L. An adverse property of a familial ALS-linked SOD1 
mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. 
Neuron 1995, 14, 1105–1116. 
35.  Higgins, C.M.; Jung, C.; Ding, H.; Xu, Z. Mutant Cu, Zn superoxide dismutase that causes 
motoneuron degeneration is present in mitochondria in the CNS. J. Neurosci. 2002, 22, RC215. 
36.  Takeuchi, H.; Kobayashi, Y.; Ishigaki, S.; Doyu, M.; Sobue, G. Mitochondrial localization of 
mutant superoxide dismutase 1 triggers caspase-dependent cell death in a cellular model of 
familial amyotrophic lateral sclerosis. J. Biol. Chem. 2002, 277, 50966–50972. 
37.  Inoue, H.; Tsukita, K.; Iwasato, T.; Suzuki, Y.; Tomioka, M.; Tateno, M.; Nagao, M.; Kawata, A.; 
Saido, T.C.; Miura, M.; et al. The crucial role of caspase-9 in the disease progression of a 
transgenic ALS mouse model. EMBO J. 2003, 22, 6665–6674. 
38.  Reyes, N.A.; Fisher, J.K.; Austgen, K.; VandenBerg, S.; Huang, E.J.; Oakes, S.A. Blocking the 
mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse 
model of amyotrophic lateral sclerosis. J. Clin. Invest. 2010, 120, 3673–3679. 
39.  Vande Velde, C.; McDonald, K.K.; Boukhedimi, Y.; McAlonis-Downes, M.; Lobsiger, C.S.;  
Bel Hadj, S.; Zandona, A.; Julien, J.P.; Shah, S.B.; Cleveland, D.W. Misfolded SOD1 associated 
with motor neuron mitochondria alters mitochondrial shape and distribution prior to clinical 
onset. PLoS One 2011, 6, e22031. 
40.  Israelson, A.; Arbel, N.; Da Cruz, S.; Ilieva, H.; Yamanaka, K.; Shoshan-Barmatz, V.;  
Cleveland, D.W. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse 
model of inherited ALS. Neuron 2010, 67, 575–587. 
41.  Misawa, H.; Nakata, K.; Matsuura, J.; Moriwaki, Y.; Kawashima, K.; Shimizu, T.; Shirasawa, T.; 
Takahashi, R. Conditional knockout of Mn superoxide dismutase in postnatal motor neurons 
reveals resistance to mitochondrial generated superoxide radicals.  Neurobiol. Dis.  2006,  
23, 169–177. 
42.  Zhu, Y.B.; Sheng, Z.H. Increased axonal mitochondrial mobility does not slow amyotrophic 
lateral sclerosis (ALS)-like disease in mutant SOD1 mice. J. Biol. Chem. 2011, 286, 23432–23440. 
43.  Chang, L.Y.; Slot, J.W.; Geuze, H.J.; Crapo, J.D. Molecular immunocytochemistry of the CuZn 
superoxide dismutase in rat hepatocytes. J. Cell Biol. 1988, 107, 2169–2179. 
44.  Saito, T.; Shinzawa, H.; Togashi, H.; Wakabayashi, H.; Ukai, K.; Takahashi, T.; Ishikawa, M.; 
Dobashi, M.; Imai, Y. Ultrastructural localization of Cu, Zn-SOD in hepatocytes of patients with 
various liver diseases. Histol. Histopathol. 1989, 4, 1–6. 
45.  Tobisawa, S.; Hozumi, Y.; Arawaka, S.; Koyama, S.; Wada, M.; Nagai, M.; Aoki, M.; Itoyama, Y.; 
Goto,  K.;  Kato, T. Mutant SOD1 linked to familial amyotrophic lateral sclerosis, but not   
wild-type SOD1, induces ER stress in COS7 cells and transgenic mice. Biochem. Biophys. Res. 
Commun. 2003, 303, 496–503. 
46.  Urushitani, M.; Sik, A.; Sakurai, T.; Nukina, N.; Takahashi, R.; Julien, J.P. Chromogranin-mediated 
secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat. 
Neurosci. 2006, 9, 108–118. Int. J. Mol. Sci. 2011, 12  6996 
 
47.  Kikuchi, H.; Almer, G.; Yamashita, S.; Guegan, C.; Nagai, M.; Xu, Z.; Sosunov, A.A.;   
McKhann, G.M., II; Przedborski, S. Spinal cord endoplasmic reticulum stress associated with a 
microsomal accumulation of mutant superoxide dismutase-1 in an ALS model. Proc. Natl. Acad. 
Sci. USA 2006, 103, 6025–6030. 
48.  Mori, A.; Yamashita, S.; Uchino, K.; Suga, T.; Ikeda, T.; Takamatsu, K.; Ishizaki, M.; Koide, T.; 
Kimura, E.; Mita, S.; et al. Derlin-1 overexpression ameliorates mutant SOD1-induced endoplasmic 
reticulum stress by reducing mutant SOD1 accumulation. Neurochem. Int. 2011, 58, 344–353. 
49.  Atkin, J.D.; Farg, M.A.; Walker, A.K.; McLean, C.; Tomas, D.;  Horne, M.K. Endoplasmic 
reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic 
lateral sclerosis. Neurobiol. Dis. 2008, 30, 400–407. 
50.  Walker, A.K.; Atkin, J.D. Stress signaling from the endoplasmic reticulum: A central player in 
the pathogenesis of amyotrophic lateral sclerosis. IUBMB Life 2011, In Press. 
51.  Sasaki, S. Endoplasmic reticulum stress in motor neurons of the spinal cord in sporadic 
amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2010, 69, 346–355. 
52.  Ito, Y.; Yamada, M.; Tanaka, H.; Aida, K.; Tsuruma, K.; Shimazawa, M.; Hozumi, I.; Inuzuka, T.; 
Takahashi, H.; Hara, H. Involvement of CHOP, an ER-stress apoptotic mediator, in both human 
sporadic ALS and ALS model mice. Neurobiol. Dis. 2009, 36, 470–476. 
53.  Saxena, S.; Cabuy, E.; Caroni, P. A role for motoneuron subtype-selective ER stress in disease 
manifestations of FALS mice. Nat. Neurosci. 2009, 12, 627–636. 
54.  Nagata, T.; Ilieva, H.; Murakami, T.; Shiote, M.; Narai, H.; Ohta, Y.; Hayashi, T.; Shoji, M.; 
Abe, K. Increased ER stress during motor neuron degeneration in a transgenic mouse model of 
amyotrophic lateral sclerosis. Neurol. Res. 2007, 29, 767–771. 
55.  Kieran, D.; Woods, I.; Villunger, A.; Strasser, A.; Prehn, J.H. Deletion of the BH3-only protein 
puma protects motoneurons from ER stress-induced apoptosis and delays motoneuron loss in 
ALS mice. Proc. Natl. Acad. Sci. USA 2007, 104, 20606–20611. 
56.  Nishitoh, H.; Kadowaki, H.; Nagai, A.; Maruyama, T.; Yokota, T.; Fukutomi, H.; Noguchi, T.; 
Matsuzawa, A.; Takeda, K.;  Ichijo, H. ALS-linked mutant SOD1 induces ER stress-  and  
ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev. 2008, 22, 1451–1464. 
57.  Atkin, J.D.; Farg, M.A.; Turner, B.J.; Tomas, D.; Lysaght, J.A.; Nunan, J.; Rembach, A.; Nagley, P.; 
Beart, P.M.; Cheema, S.S. et al. Induction of the unfolded protein response in familial 
amyotrophic lateral sclerosis and association of protein-disulfide  isomerase with superoxide 
dismutase 1. J. Biol. Chem. 2006, 281, 30152–30165. 
58.  Turner, B.J.; Atkin, J.D. ER stress and UPR in familial amyotrophic lateral sclerosis. Curr. Mol. 
Med. 2006, 6, 79–86. 
59.  Mourelatos, Z.; Adler, H.; Hirano, A.; Donnenfeld, H.; Gonatas, J.O.;  Gonatas, N.K. 
Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis revealed 
by organelle-specific antibodies. Proc. Natl. Acad. Sci. USA 1990, 87, 4393–4395. 
60.  Lafon-Cazal, M.; Adjali, O.; Galéotti, N.; Poncet, J.; Jouin, P.; Homburger, V.; Bockaert, J.; 
Marin, P. Proteomic analysis of astrocytic secretion in the mouse. Comparison with the 
cerebrospinal fluid proteome. J. Biol. Chem. 2003, 278, 24438–24448. Int. J. Mol. Sci. 2011, 12  6997 
 
61.  Turner, B.J.; Atkin, J.D.; Farg, M.A.; Zang da, W.; Rembach, A.; Lopes, E.C.; Patch, J.D.;   
Hill, A.F.;  Cheema, S.S. Impaired extracellular secretion of mutant superoxide dismutase 1 
associates with neurotoxicity in familial amyotrophic lateral sclerosis. J. Neurosci.  2005,  
25, 108–117. 
62.  Durham, H.D.; Roy, J.; Dong, L.; Figlewicz, D.A. Aggregation of mutant Cu/Zn superoxide 
dismutase proteins in a culture model of ALS. J. Neuropathol. Exp. Neurol. 1997, 56, 523–530. 
63.  Matsumoto, G.; Stojanovic, A.; Holmberg, C.I.; Kim, S.; Morimoto, R.I. Structural properties 
and neuronal toxicity of amyotrophic lateral sclerosis-associated Cu/Zn superoxide dismutase 1 
aggregates. J. Cell Biol. 2005, 171, 75–85. 
64.  Pramatarova, A.; Laganière, J.; Roussel, J.; Brisebois, K.;  Rouleau, G.A. Neuron-specific 
expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor 
impairment. J. Neurosci. 2001, 21, 3369–3374. 
65.  Wang, L.J.; Lu, Y.Y.; Muramatsu, S.; Ikeguchi, K.; Fujimoto, K.; Okada, T.; Mizukami, H.; 
Matsushita, T.; Hanazono, Y.; Kume, A.; et al. Neuroprotective effects of glial cell line-derived 
neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of 
amyotrophic lateral sclerosis. J. Neurosci. 2002, 22, 6920–6928. 
66.  Gong, Y.H.; Parsadanian, A.S.; Andreeva, A.; Snider, W.D.; Elliott, J.L. Restricted expression of 
G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause 
motoneuron degeneration. J. Neurosci. 2000, 20, 660–665. 
67.  Clement, A.M.; Nguyen, M.D.; Roberts, E.A.; Garcia, M.L.; Boillée, S.; Rule, M.; McMahon, A.P.; 
Doucette, W.; Siwek, D.; Ferrante, R.J.; et al. Wild-type nonneuronal cells extend survival of 
SOD1 mutant motor neurons in ALS mice. Science 2003, 302, 113–117. 
68.  Yamanaka, K.; Chun, S.J.; Boillee, S.; Fujimori-Tonou, N.; Yamashita, H.; Gutmann, D.H.; 
Takahashi, R.; Misawa, H.; Cleveland, D.W. Astrocytes as determinants of disease progression 
in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008, 11, 251–253. 
69.  Wang, L.; Gutmann, D.H.; Roos, R.P. Astrocyte loss of mutant SOD1 delays ALS disease onset 
and progression in G85R transgenic mice. Hum. Mol. Genet. 2011, 20, 286–293. 
70.  Wang, L.; Sharma, K.; Deng, H.X.; Siddique, T.; Grisotti, G.; Liu, E.; Roos, R.P. Restricted 
expression of mutant SOD1 in spinal motor neurons and interneurons induces motor neuron 
pathology. Neurobiol. Dis. 2008, 29, 400–408. 
71.  Nagai, M.; Re, D.B.; Nagata, T.; Chalazonitis, A.; Jessell, T.M.; Wichterle, H.; Przedborski, S. 
Astrocytes expressing ALS-linked  mutated SOD1 release factors selectively toxic to motor 
neurons. Nat. Neurosci. 2007, 10, 615–622. 
72.  Di Giorgio, F.P.; Carrasco, M.A.; Siao, M.C.; Maniatis, T.; Eggan, K. Non-cell autonomous 
effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci. 
2007, 10, 608–614. 
73.  Di Giorgio, F.P.; Boulting, G.L.; Bobrowicz, S.;  Eggan, K.C. Human embryonic stem   
cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing 
mutation. Cell Stem Cell 2008, 3, 637–648. 
74.  Zhao, W.; Xie, W.; Xiao, Q.; Beers, D.R.; Appel, S.H. Protective effects of an anti-inflammatory 
cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. J. Neurochem. 
2006, 99, 1176–1187. Int. J. Mol. Sci. 2011, 12  6998 
 
75.  Zhao, W.; Beers, D.R.; Henkel, J.S.; Zhang, W.; Urushitani, M.; Julien, J.P.;  Appel, S.H. 
Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 2010, 58, 231–243. 
76.  Ezzi, S.A.; Larivière, R.; Urushitani, M.; Julien, J.P. Neuronal over-expression of chromogranin 
A accelerates disease onset in a mouse model of ALS. J. Neurochem. 2010, 115, 1102–1111. 
77.  Liu, H.N.; Sanelli, T.; Horne, P.; Pioro, E.P.; Strong, M.J.; Rogaeva, E.; Bilbao, J.; Zinman, L.; 
Robertson, J. Lack of evidence of monomer/misfolded superoxide dismutase-1 in sporadic 
amyotrophic lateral sclerosis. Ann. Neurol. 2009, 66, 75–80. 
78.  Zetterström, P.; Andersen, P.M.; Brännström, T.;  Marklund, S.L. Misfolded superoxide 
dismutase-1 in CSF from amyotrophic lateral sclerosis patients. J. Neurochem. 2011, 117, 91–99. 
79.  Ezzi, S.A.; Urushitani, M.; Julien, J.P. Wild-type superoxide dismutase acquires binding and 
toxic properties of ALS-linked mutant forms through oxidation. J. Neurochem. 2007, 102, 170–178. 
80.  Gruzman, A.; Wood, W.L.; Alpert, E.; Prasad, M.D.; Miller, R.G.; Rothstein, J.D.; Bowser, R.; 
Hamilton, R.; Wood, T.D.; Cleveland, D.W.; et al. Common molecular signature in SOD1 for 
both sporadic and familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA  2007,  
104, 12524–12529. 
81.  Bosco, D.A.; Morfini, G.; Karabacak, N.M.; Song, Y.; Gros-Louis, F.; Pasinelli, P.; Goolsby, H.; 
Fontaine, B.A.; Lemay, N.; McKenna-Yasek, D.;  et al. Wild-type and mutant SOD1 share   
an aberrant conformation and a common pathogenic pathway in  ALS.  Nat. Neurosci.  2010,  
13, 1396–1403. 
82.  Haidet-Phillips, A.M.; Hester, M.E.; Miranda, C.J.; Meyer, K.; Braun, L.; Frakes, A.; Song, S.; 
Likhite, S.; Murtha, M.J.; Foust, K.D.; et al. Astrocytes from familial and sporadic ALS patients 
are toxic to motor neurons. Nat. Biotechnol. 2011, 29, 824–828. 
83.  Arai, T.; Hasegawa, M.; Akiyama, H.; Ikeda, K.; Nonaka, T.; Mori, H.; Mann, D.; Tsuchiya, K.; 
Yoshida, M.; Hashizume, Y.; et al. TDP-43 is a component of ubiquitin-positive tau-negative 
inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. 
Biophys. Res. Commun. 2006, 351, 602–611. 
84.  Neumann, M.; Sampathu, D.M.; Kwong, L.K.; Truax, A.C.; Micsenyi, M.C.; Chou, T.T.; Bruce, J.; 
Schuck, T.; Grossman, M.; Clark, C.M.; et al. Ubiquitinated TDP-43 in frontotemporal lobar 
degeneration and amyotrophic lateral sclerosis. Science 2006, 314, 130–133. 
85.  Borroni, B.; Bonvicini, C.; Alberici, A.; Buratti, E.; Agosti, C.; Archetti, S.; Papetti, A.;   
Stuani, C.; Di Luca, M.; Gennarelli, M.; et al. Mutation within TARDBP leads to frontotemporal 
dementia without motor neuron disease. Hum. Mutat. 2009, 30, E974–E983. 
86.  Benajiba, L.; Le Ber, I.; Camuzat, A.; Lacoste, M.; Thomas-Anterion, C.; Couratier, P.; Legallic, S.; 
Salachas, F.; Hannequin, D.; Decousus, M.; et al. TARDBP mutations in motoneuron disease 
with frontotemporal lobar degeneration. Ann. Neurol. 2009, 65, 470–473. 
87.  Quadri, M.; Cossu, G.; Saddi, V.; Simons, E.J.; Murgia, D.; Melis, M.; Ticca, A.; Oostra, B.A.; 
Bonifati,  V. Broadening the phenotype of TARDBP mutations: The  TARDBP Ala382Thr 
mutation and Parkinson’s disease in Sardinia. Neurogenetics 2011, 12, 203–209. 
88.  Buratti, E.; Dork, T.; Zuccato, E.; Pagani, F.; Romano, M.; Baralle, F.E. Nuclear factor TDP-43 
and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001, 20, 1774–1784. Int. J. Mol. Sci. 2011, 12  6999 
 
89.  Strong, M.J.; Volkening, K.; Hammond, R.; Yang, W.; Strong, W.; Leystra-Lantz, C.;  
Shoesmith, C. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding 
protein. Mol. Cell. Neurosci. 2007, 35, 320–327. 
90.  Rogelj, B.; Briese, M.; Cereda, M.; Kayikci, M.; König, J.; Hortobágyi, T.; Nishimura, A.L.; 
Zupunski, V.; Patani, R.; Chandran, S.;  et al. Characterizing the RNA targets and   
position-dependent splicing regulation by TDP-43. Nat. Neurosci. 2011, 14, 452–458. 
91.  Polymenidou, M.; Lagier-Tourenne, C.; Hutt, K.R.; Huelga, S.C.; Moran, J.; Liang, T.Y.; Ling, S.C.; 
Sun, E.; Wancewicz, E.; Mazur, C.; et al. Long pre-mRNA depletion and RNA missplicing 
contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 2011, 14, 459–468. 
92.  Xiao, S.; Sanelli, T.; Dib, S.; Sheps, D.; Findlater, J.; Bilbao, J.; Keith, J.; Zinman, L.;   
Rogaeva, E.; Robertson, J. RNA targets of TDP-43 identified by UV-CLIP are deregulated in 
ALS. Mol. Cell. Neurosci. 2011, 47, 167–180. 
93.  Ayala, Y.M.; Misteli, T.; Baralle, F.E. TDP-43 regulates retinoblastoma protein phosphorylation 
through the repression of cyclin-dependent kinase 6 expression. Proc. Natl. Acad. Sci. USA 2008, 
105, 3785–3789. 
94.  Fiesel, F.C.; Voigt, A.; Weber, S.S.; Van den Haute, C.; Waldenmaier, A.; Görner, K.; Walter, M.; 
Anderson, M.L.; Kern, J.V.; Rasse, T.M.;  et al. Knockdown of transactive response   
DNA-binding protein (TDP-43) downregulates histone deacetylase 6. EMBO J.  2010,  
29, 209–221. 
95.  Iguchi, Y.; Katsuno, M.; Niwa, J.; Yamada, S.; Sone, J.; Waza, M.; Adachi, H.; Tanaka, F.; 
Nagata, K.; Arimura, N. TDP-43 depletion induces neuronal cell damage through dysregulation 
of Rho family GTPases. J. Biol. Chem. 2009, 284, 22059–22066. 
96.  Anthony, K.; Gallo, J.M. Aberrant RNA processing events in neurological disorders. Brain Res. 
2010, 1338, 67–77. 
97.  Urushitani, M.; Sato, T.; Bamba, H.; Hisa, Y.;  Tooyama, I. Synergistic effect between 
proteasome and autophagosome in the clearance of polyubiquitinated TDP-43. J. Neurosci. Res. 
2010, 88, 784–797. 
98.  Mackenzie, I.R.; Bigio, E.H.; Ince, P.G.; Geser, F.; Neumann, M.; Cairns, N.J.; Kwong, L.K.; 
Forman, M.S.; Ravits, J.; Stewart, H.;  et al. Pathological TDP-43 distinguishes sporadic 
amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. 
Neurol. 2007, 61, 427–434. 
99.  Sumi, H.; Kato, S.; Mochimaru, Y.; Fujimura, H.; Etoh, M.; Sakoda, S. Nuclear TAR DNA 
binding protein 43 expression in spinal cord neurons correlates with the clinical course in 
amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2009, 68, 37–47. 
100.  Okamoto, Y.; Ihara, M.; Urushitani, M.; Yamashita, H.; Kondo, T.; Tanigaki, A.; Oono, M.; 
Komatsu, K.; Kawamata, J.; Ikemoto, A.; et al. An autopsy case of SOD1-related ALS with 
TDP-43 positive inclusions. Neurology 2011, in press. 
101.  Wider, C.; Dickson, D.W.; Stoessl, A.J.; Tsuboi, Y.; Chapon, F.; Gutmann, L.; Lechevalier, B.; 
Calne, D.B.; Personett, D.A.; Hulihan, M.;  et al. Pallidonigral TDP-43 pathology in Perry 
syndrome. Parkinsonism Relat. Disord. 2009, 15, 281–286. Int. J. Mol. Sci. 2011, 12  7000 
 
102.  Nakashima-Yasuda, H.; Uryu, K.; Robinson, J.; Xie, S.X.; Hurtig, H.; Duda, J.E.; Arnold, S.E.; 
Siderowf, A.; Grossman, M.; Leverenz, J.B.; et al. Co-morbidity of TDP-43 proteinopathy in 
Lewy body related diseases. Acta Neuropathol. (Berl.) 2007, 114, 221–229. 
103.  Schwab, C.; Arai, T.; Hasegawa, M.; Yu, S.;  McGeer, P.L. Colocalization of   
transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington 
disease. J. Neuropathol. Exp. Neurol. 2008, 67, 1159–1165. 
104.  Weihl, C.C.; Temiz, P.; Miller, S.E.; Watts, G.; Smith, C.; Forman, M.; Hanson, P.I.; Kimonis, V.; 
Pestronk, A. TDP-43 accumulation in inclusion body myopathy muscle suggests a common 
pathogenic mechanism with frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 2008,  
79, 1186–1189. 
105.  Sato, T.; Takeuchi, S.; Saito, A.; Ding, W.; Bamba, H.; Matsuura, H.; Hisa, Y.; Tooyama, I.; 
Urushitani, M. Axonal ligation induces transient redistribution of TDP-43 in brainstem motor 
neurons. Neuroscience 2009, 164, 1565–1578. 
106.  Moisse, K.; Volkening, K.; Leystra-Lantz, C.; Welch, I.; Hill, T.; Strong, M.J. Divergent patterns 
of cytosolic TDP-43 and neuronal progranulin expression following axotomy: Implications for 
TDP-43 in the physiological response to neuronal injury. Brain Res. 2009, 1249, 202–211. 
107.  Nishimura, A.L.; Zupunski, V.; Troakes, C.; Kathe, C.; Fratta, P.; Howell, M.; Gallo, J.M.; 
Hortobágyi, T.; Shaw, C.E.;  Rogelj, B. Nuclear import impairment causes cytoplasmic   
trans-activation response DNA-binding protein accumulation and is associated with 
frontotemporal lobar degeneration. Brain 2010, 133, 1763–1771. 
108.  Winton, M.J.; Igaz, L.M.; Wong, M.M.; Kwong, L.K.; Trojanowski, J.Q.; Lee, V.M. Disturbance 
of nuclear and cytoplasmic Tar DNA binding protein (TDP-43) induces disease-like redistribution, 
sequestration and aggregate formation. J. Biol. Chem. 2008, 283, 13302–13309. 
109.  Zhang, Y.J.; Xu, Y.F.; Dickey, C.A.; Buratti, E.; Baralle, F.; Bailey, R.; Pickering-Brown, S.; 
Dickson, D.;  Petrucelli, L. Progranulin mediates caspase-dependent cleavage of TAR DNA 
binding protein-43. J. Neurosci. 2007, 27, 10530–10534. 
110.  Nishimoto, Y.; Ito, D.; Yagi, T.; Nihei, Y.; Tsunoda, Y.;  Suzuki, N. Characterization of 
alternative isoforms and inclusion body of the TAR DNA-binding protein-43. J. Biol. Chem. 
2010, 285, 608–619. 
111.  Igaz, L.M.; Kwong, L.K.; Xu, Y.; Truax, A.C.; Uryu, K.; Neumann, M.;  Clark, C.M.;   
Elman, L.B.; Miller, B.L.; Grossman, M.; et al. Enrichment of C-Terminal fragments in TAR 
DNA-Binding Protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal 
lobar degeneration and amyotrophic lateral sclerosis. Am. J. Pathol. 2008, 173, 182–194. 
112.  Nonaka, T.; Kametani, F.; Arai, T.; Akiyama, H.; Hasegawa, M. Truncation and pathogenic 
mutations facilitate the formation of intracellular aggregates of TDP-43. Hum. Mol. Genet. 2009, 
18, 3353–3364. 
113.  Johnson, B.S.; Snead, D.; Lee, J.J.; McCaffery, J.M.; Shorter, J.;  Gitler, A.D. TDP-43 is 
intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate 
aggregation and increase toxicity. J. Biol. Chem. 2009, 284, 20329–20339. 
114.  Furukawa, Y.; Kaneko, K.; Watanabe, S.; Yamanaka, K.;  Nukina, N. A seeding reaction 
recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element 
(TAR) DNA-binding protein-43 inclusions. J. Biol. Chem. 2011, 286, 18664–18672. Int. J. Mol. Sci. 2011, 12  7001 
 
115.  Yang, C.; Tan, W.; Whittle, C.; Qiu, L.; Cao, L.; Akbarian, S.; Xu, Z. The C-Terminal TDP-43 
fragments have a high aggregation propensity and harm neurons by a dominant-negative 
mechanism. PLoS One 2010, 5, e15878. 
116.  Pesiridis, G.S.; Tripathy, K.; Tanik, S.; Trojanowski, J.Q.; Lee, V.M. A “two-hit” hypothesis for 
inclusion formation by carboxyl-terminal fragments of TDP-43 protein linked to RNA depletion 
and impaired microtubule-dependent transport. J. Biol. Chem. 2011, 286, 18845–18855. 
117.  Shiina, Y.; Arima, K.; Tabunoki, H.; Satoh, J. TDP-43 dimerizes in human cells in culture. Cell. 
Mol. Neurobiol. 2010, 30, 641–652.  
118.  Johnson, B.S.; McCaffery, J.M.; Lindquist, S.;  Gitler, A.D. A yeast TDP-43 proteinopathy 
model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc. 
Natl. Acad. Sci. USA 2008, 105, 6439–6444. 
119.  Igaz, L.M.; Kwong, L.K.; Lee, E.B.; Chen-Plotkin, A.; Swanson, E.; Unger, T.; Malunda, J.;  
Xu, Y.; Winton, M.J.; Trojanowski, J.Q.;  et al. Dysregulation of the ALS-associated gene   
TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Invest. 2011, 121, 726–738. 
120.  Ash, P.E.; Zhang, Y.J.; Roberts, C.M.; Saldi, T.; Hutter, H.; Buratti, E.; Petrucelli, L.; Link, C.D. 
Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum. Mol. Genet. 2010, 19, 3206–3218. 
121.  Wegorzewska, I.; Bell, S.; Cairns, N.J.; Miller, T.M.; Baloh, R.H. TDP-43 mutant transgenic 
mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA 
2009, 106, 18809–18814. 
122.  Xu, Y.F.; Gendron, T.F.; Zhang, Y.J.; Lin, W.L.; D’Alton, S.; Sheng, H.; Casey, M.C.; Tong, J.; 
Knight, J.; Yu, X.; et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, 
mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci. 
2010, 30, 10851–10859. 
123. University of Tokyo. ALS Mutation Database, 2011. Available online: https://reseq.lifesciencedb. 
jp/resequence/GeneDetail.do?targetId=1&geneId=EG23435 (accessed on 12 October 2011). 
124.  Kabashi, E.; Valdmanis, P.N.; Dion, P.; Spiegelman, D.; McConkey, B.J.; Velde, C.V.;   
Bouchard, J.P.; Lacomblez, L.; Pochigaeva, K.; Salachas, F.;  et al. TARDBP mutations in 
individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008, 40, 572–574. 
125.  Kabashi, E.; Lin, L.; Tradewell, M.L.; Dion, P.A.; Bercier, V.; Bourgouin, P.; Rochefort, D.;  
Bel Hadj, S.; Durham, H.D.; Vande Velde, C.; et al. Gain and loss of function of ALS-related 
mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum. Mol. Genet. 2010, 19, 671–683. 
126.  Sreedharan, J.; Blair, I.P.; Tripathi, V.B.; Hu, X.; Vance, C.; Rogelj, B.; Ackerley, S.;   
Durnall, J.C.; Williams, K.L.; Buratti, E.;  et al. TDP-43  mutations in familial and sporadic 
amyotrophic lateral sclerosis. Science 2008, 319, 1668–1672. 
127.  Rutherford, N.J.; Zhang, Y.J.; Baker, M.; Gass, J.M.; Finch, N.A.; Xu, Y.F.; Stewart, H.;   
Kelley, B.J.; Kuntz, K.; Crook, R.J.; et al. Novel mutations in TARDBP (TDP-43) in patients 
with familial amyotrophic lateral sclerosis. PLoS Genet. 2008, 4, e1000193. 
128.  Liachko, N.F.; Guthrie, C.R.;  Kraemer, B.C. Phosphorylation promotes neurotoxicity in a 
Caenorhabditis elegans model of TDP-43 proteinopathy. J. Neurosci. 2010, 30, 16208–16219. 
129.  Zhou, H.; Huang, C.; Chen, H.; Wang, D.; Landel, C.P.; Xia, P.Y.; Bowser, R.; Liu, Y.J.;  
Xia, X.G. Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS 
Genet. 2010, 6, e1000887. Int. J. Mol. Sci. 2011, 12  7002 
 
130.  Stallings, N.R.; Puttaparthi, K.; Luther, C.M.; Burns, D.K.;  Elliott, J.L. Progressive motor 
weakness in transgenic mice expressing human TDP-43. Neurobiol. Dis. 2010, 40, 404–414. 
131.  Swarup, V.; Phaneuf, D.; Bareil, C.; Robertson, J.; Rouleau, G.A.; Kriz, J.;  Julien, J.P. 
Pathological  hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in 
transgenic mice produced with TDP-43 genomic fragments. Brain 2011, doi:10.1093/brain/awr159. 
132.  Liu-Yesucevitz, L.; Bilgutay, A.; Zhang, Y.J.; Vanderwyde, T.; Citro, A.; Mehta, T.; Zaarur, N.; 
McKee, A.; Bowser, R.; Sherman, M.; et al. Tar DNA binding protein-43 (TDP-43) associates 
with stress granules: Analysis of cultured cells and pathological brain tissue. PLoS One 2010,  
5, e13250. 
133.  Guerreiro, R.J.; Schymick, J.C.; Crews, C.; Singleton, A.; Hardy, J.; Traynor, B.J. TDP-43 is not 
a common cause of sporadic amyotrophic lateral sclerosis. PLoS One 2008, 3, e2450. 
134.  Gijselinck, I.; Sleegers, K.; Engelborghs, S.; Robberecht, W.; Martin, J.J.; Vandenberghe, R.; 
Sciot, R.; Dermaut, B.; Goossens, D.; van der Zee, J.; et al. Neuronal inclusion protein TDP-43 
has no primary genetic role in FTD and ALS. Neurobiol. Aging 2009, 30, 1329–1331. 
135.  Corrado, L.; Ratti, A.; Gellera, C.; Buratti, E.; Castellotti, B.; Carlomagno, Y.; Ticozzi, N.; 
Mazzini, L.; Testa, L.; Taroni, F.; et al. High frequency of TARDBP gene mutations in Italian 
patients with amyotrophic lateral sclerosis. Hum. Mutat. 2009, 30, 688–694. 
136.  Lagier-Tourenne, C.; Cleveland, D.W. Rethinking ALS: the FUS about  TDP-43.  Cell  2009,  
136, 1001–1004. 
137.  Van Deerlin, V.M.; Leverenz, J.B.; Bekris, L.M.; Bird, T.D.; Yuan, W.; Elman, L.B.; Clay, D.; 
Wood, E.M.; Chen-Plotkin, A.S.; Martinez-Lage, M.; et al. TARDBP mutations in amyotrophic 
lateral sclerosis with TDP-43 neuropathology: A genetic and histopathological analysis. Lancet. 
Neurol. 2008, 7, 409–416. 
138.  Aguzzi, A.; Rajendran, L. The transcellular spread of cytosolic amyloids, prions, and prionoids. 
Neuron 2009, 64, 783–790. 
139.  Frost, B.;  Diamond, M.I. Prion-like mechanisms in neurodegenerative diseases. Nat. Rev. 
Neurosci. 2010, 11, 155–159. 
140.  Frost, B.; Ollesch, J.; Wille, H.; Diamond, M.I. Conformational diversity of wild-type Tau fibrils 
specified by templated conformation change. J. Biol. Chem. 2009, 284, 3546–3551. 
141.  Desplats, P.; Lee, H.J.; Bae, E.J.; Patrick, C.; Rockenstein, E.; Crews, L.; Spencer, B.; Masliah, E.; 
Lee, S.J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of 
alpha-synuclein. Proc. Natl. Acad. Sci. USA 2009, 106, 13010–13015. 
142.  Ren, P.H.; Lauckner, J.E.; Kachirskaia, I.; Heuser, J.E.; Melki, R.; Kopito, R.R. Cytoplasmic 
penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell 
Biol. 2009, 11, 219–225. 
143.  Münch, C.; O’Brien, J.; Bertolotti, A. Prion-like propagation of mutant superoxide dismutase-1 
misfolding in neuronal cells. Proc. Natl. Acad. Sci. USA 2011, 108, 3548–3553. 
144.  Chia, R.; Tattum, M.H.; Jones, S.; Collinge, J.; Fisher, E.M.;  Jackson, G.S. Superoxide 
dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death 
mechanism in amyotrophic lateral sclerosis. PLoS One 2010, 5, e10627. Int. J. Mol. Sci. 2011, 12  7003 
 
145.  Grad, L.I.; Guest, W.C.; Yanai, A.; Pokrishevsky, E.; O’Neill, M.A.; Gibbs, E.; Semenchenko, V.; 
Yousefi, M.; Wishart, D.S.; Plotkin, S.S.;  et al. Intermolecular transmission of superoxide 
dismutase 1 misfolding in living cells. Proc. Natl. Acad. Sci. USA 2011, 108, 16398–16403. 
146.  Urushitani, M.; Ezzi, S.A.;  Julien, J.P. Therapeutic  effects of immunization with mutant 
superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. 
USA 2007,104, 2495–2500. 
147.  Takeuchi, S.; Fujiwara, N.; Ido, A.; Oono, M.; Takeuchi, Y.; Tateno, M.; Suzuki, K.; Takahashi, R.; 
Tooyama, I.; Taniguchi, N. et al. Induction of protective immunity by vaccination with wild-type 
apo superoxide dismutase 1 in mutant SOD1 transgenic mice. J. Neuropathol. Exp. Neurol. 2010, 
69, 1044–1056. 
148.  Gros-Louis, F.; Soucy, G.; Larivière, R.;  Julien, J.P. Intracerebroventricular infusion of 
monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant 
delays mortality in a mouse model of ALS. J. Neurochem. 2010, 113, 1188–1199. 
149.  Che, M.X.; Jiang, Y.J.; Xie, Y.Y.; Jiang, L.L.; Hu, H.Y. Aggregation of the 35-kDa fragment of 
TDP-43 causes formation of cytoplasmic inclusions and alteration of RNA processing. FASEB J. 
2011, 25, 2344–2353. 
150.  Noto, Y.; Shibuya, K.; Sato, Y.; Kanai, K.; Misawa, S.; Sawai, S.; Mori, M.; Uchiyama, T.;  
Isose, S.; Nasu, S.; et al. Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: Specificity, 
sensitivity, and a possible prognostic value. Amyotroph. Lateral Scler. 2011, 12, 140–143. 
151.  Steinacker, P.; Hendrich, C.; Sperfeld, A.D.; Jesse, S.; von Arnim, C.A.; Lehnert, S.; Pabst, A.; 
Uttner, I.; Tumani, H.; Lee, V.M.;  et al. TDP-43 in cerebrospinal fluid of patients with 
frontotemporal  lobar degeneration and amyotrophic lateral sclerosis. Arch. Neurol.  2008,  
65, 1481–1487. 
152.  Kasai, T.; Tokuda, T.; Ishigami, N.; Sasayama, H.; Foulds, P.; Mitchell, D.J.; Mann, D.M.; 
Allsop, D.;  Nakagawa, M. Increased TDP-43 protein in cerebrospinal fluid of patients with 
amyotrophic lateral sclerosis. Acta Neuropathol. (Berl.) 2009, 117, 55–62. 
© 2011  by the authors; licensee MDPI, Basel, Switzerland. This article is an open  access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 